Skip to main content
Top
Published in: Gastric Cancer 3/2016

Open Access 01-07-2016 | Original Article

CD97 promotion of gastric carcinoma lymphatic metastasis is exosome dependent

Authors: Daren Liu, Chao Li, Bogusz Trojanowicz, Xiaowen Li, Dike Shi, Chenni Zhan, Zhefang Wang, Li Chen

Published in: Gastric Cancer | Issue 3/2016

Login to get access

Abstract

Background

CD97 knockdown impairs the metastatic capacity of SGC-7901 gastric cancer cells. However, the role of CD97 in the distant lymphatic premetastatic niche formation of gastric cancer remains unknown.

Methods

Exosomes and the soluble fraction were isolated from SGC-L (an SGC-7901-cell-derived highly lymphatic metastatic cell line) and CD97-knockdown (SGC-L/CD97-kd) cells, and were co-cultured with gastric cancer cells. The metastatic capacity of the two cell lines was evaluated in vitro and in a footpad lymph node metastasis mouse model. Premetastatic-niche-formation-related proteins were examined immunohistochemically.

Results

CD97 expression was ninefold higher in SGC-L cells than in SGC-7901 cells. In vitro, exosomes or conditioned medium from the SGC-L cells enhanced cell proliferation (20 % increase) and invasion (30 % increase) as compared with that from SGC-L/CD97-kd cells (p < 0.01). Intrafootpad injections of SGC-L, but not SGC-L/CD97-kd exosomes or conditioned medium, strongly promoted SGC-L and SGC-L/CD97-kd cell accumulation in the draining lymph nodes (p < 0.01) and increased CD55, CD44v6, α5β1, CD31, epithelial cell adhesion molecule, and CD151 expression. Although the SGC-L/CD97-kd exosomes alone were insufficient for promotion of metastasis, they were partly aided by the SGC-L-cell-derived soluble fraction.

Conclusions

The CD97 small isoform promotes SGC-L cell lymphatic metastasis exosome dependently, and aided by the soluble fraction, the exosome-dependent CD97 plays a pivotal role in premetastatic niche formation.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Bissell MJ, Labarge MA. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell. 2005;7:17–23.PubMedPubMedCentral Bissell MJ, Labarge MA. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell. 2005;7:17–23.PubMedPubMedCentral
3.
go back to reference Aust G, Steinert M, Schutz A, Boltze C, Wahlbuhl M, Hamann J, et al. CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas. Am J Clin Pathol. 2002;118:699–707.CrossRefPubMed Aust G, Steinert M, Schutz A, Boltze C, Wahlbuhl M, Hamann J, et al. CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas. Am J Clin Pathol. 2002;118:699–707.CrossRefPubMed
4.
go back to reference Liu Y, Chen L, Peng SY, Chen ZX, Hoang-Vu C. Role of CD97stalk and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients. J Zhejiang Univ Sci B. 2005;6:913–8.CrossRefPubMedPubMedCentral Liu Y, Chen L, Peng SY, Chen ZX, Hoang-Vu C. Role of CD97stalk and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients. J Zhejiang Univ Sci B. 2005;6:913–8.CrossRefPubMedPubMedCentral
5.
go back to reference Liu Y, Chen L, Peng S, Chen Z, Gimm O, Finke R, et al. The expression of CD97EGF and its ligand CD55 on marginal epithelium is related to higher stage and depth of tumor invasion of gastric carcinomas. Oncol Rep. 2005;14:1413–20.PubMed Liu Y, Chen L, Peng S, Chen Z, Gimm O, Finke R, et al. The expression of CD97EGF and its ligand CD55 on marginal epithelium is related to higher stage and depth of tumor invasion of gastric carcinomas. Oncol Rep. 2005;14:1413–20.PubMed
6.
go back to reference Liu D, Trojanowicz B, Radestock Y, Fu T, Hammje K, Chen L, et al. Role of CD97 isoforms in gastric carcinoma. Int J Oncol. 2010;36:1401–8.CrossRefPubMed Liu D, Trojanowicz B, Radestock Y, Fu T, Hammje K, Chen L, et al. Role of CD97 isoforms in gastric carcinoma. Int J Oncol. 2010;36:1401–8.CrossRefPubMed
7.
go back to reference Liu D, Trojanowicz B, Ye L, Li C, Zhang L, Li X, et al. The invasion and metastasis promotion role of CD97 small isoform in gastric carcinoma. PLoS One. 2012;7:e39989.CrossRefPubMedPubMedCentral Liu D, Trojanowicz B, Ye L, Li C, Zhang L, Li X, et al. The invasion and metastasis promotion role of CD97 small isoform in gastric carcinoma. PLoS One. 2012;7:e39989.CrossRefPubMedPubMedCentral
8.
go back to reference Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta. 2012;1820:940–8.CrossRefPubMed Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta. 2012;1820:940–8.CrossRefPubMed
9.
go back to reference Simons M, Raposo G. Exosomes–vesicular carriers for intercellular communication. Curr Opin Cell Biol. 2009;21:575–81.CrossRefPubMed Simons M, Raposo G. Exosomes–vesicular carriers for intercellular communication. Curr Opin Cell Biol. 2009;21:575–81.CrossRefPubMed
10.
go back to reference Suetsugu A, Honma K, Saji S, Moriwaki H, Ochiya T, Hoffman RM. Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. Adv Drug Deliv Rev. 2013;65:383–90.CrossRefPubMed Suetsugu A, Honma K, Saji S, Moriwaki H, Ochiya T, Hoffman RM. Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. Adv Drug Deliv Rev. 2013;65:383–90.CrossRefPubMed
11.
go back to reference Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102:1555–77.CrossRefPubMedPubMedCentral Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102:1555–77.CrossRefPubMedPubMedCentral
12.
go back to reference Uyama R, Hong SH, Nakagawa T, Yazawa M, Kadosawa T, Mochizuki M, et al. Establishment and characterization of eight feline mammary adenocarcinoma cell lines. J Vet Med Sci. 2005;67:1273–6.CrossRefPubMed Uyama R, Hong SH, Nakagawa T, Yazawa M, Kadosawa T, Mochizuki M, et al. Establishment and characterization of eight feline mammary adenocarcinoma cell lines. J Vet Med Sci. 2005;67:1273–6.CrossRefPubMed
13.
go back to reference Gauduchon J, Gouilleux F, Maillard S, Marsaud V, Renoir JM, Sola B. 4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members. Clin Cancer Res. 2005;11:2345–54.CrossRefPubMed Gauduchon J, Gouilleux F, Maillard S, Marsaud V, Renoir JM, Sola B. 4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members. Clin Cancer Res. 2005;11:2345–54.CrossRefPubMed
14.
15.
go back to reference Subra C, Grand D, Laulagnier K, Stella A, Lambeau G, Paillasse M, et al. Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins. J Lipid Res. 2010;51:2105–20.CrossRefPubMedPubMedCentral Subra C, Grand D, Laulagnier K, Stella A, Lambeau G, Paillasse M, et al. Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins. J Lipid Res. 2010;51:2105–20.CrossRefPubMedPubMedCentral
16.
go back to reference Cho JA, Lee YS, Kim SH, Ko JK, Kim CW. MHC independent anti-tumor immune responses induced by Hsp70-enriched exosomes generate tumor regression in murine models. Cancer Lett. 2009;275:256–65.CrossRefPubMed Cho JA, Lee YS, Kim SH, Ko JK, Kim CW. MHC independent anti-tumor immune responses induced by Hsp70-enriched exosomes generate tumor regression in murine models. Cancer Lett. 2009;275:256–65.CrossRefPubMed
17.
go back to reference Jung T, Castellana D, Klingbeil P, Cuesta Hernández I, Vitacolonna M, Orlicky DJ, et al. CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia. 2009;11:1093–105.CrossRefPubMedPubMedCentral Jung T, Castellana D, Klingbeil P, Cuesta Hernández I, Vitacolonna M, Orlicky DJ, et al. CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia. 2009;11:1093–105.CrossRefPubMedPubMedCentral
18.
go back to reference Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008;7:504–16.CrossRefPubMed Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008;7:504–16.CrossRefPubMed
19.
go back to reference Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Lee HJ, et al. Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target. Clin Exp Metastasis. 2008;25:89–96.CrossRefPubMed Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Lee HJ, et al. Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target. Clin Exp Metastasis. 2008;25:89–96.CrossRefPubMed
20.
go back to reference Zöller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 2009;9:40–55.CrossRefPubMed Zöller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 2009;9:40–55.CrossRefPubMed
21.
go back to reference Detchokul S, Williams ED, Parker MW, Frauman AG. Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies. Br J Pharmacol. 2014;171:5462–90.CrossRefPubMedPubMedCentral Detchokul S, Williams ED, Parker MW, Frauman AG. Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies. Br J Pharmacol. 2014;171:5462–90.CrossRefPubMedPubMedCentral
22.
go back to reference van Deventer HW, Palmieri DA, Wu QP, McCook EC, Serody JS. Circulating fibrocytes prepare the lung for cancer metastasis by recruiting Ly-6C+ monocytes via CCL2. J Immunol. 2013;190:4861–7.CrossRefPubMedPubMedCentral van Deventer HW, Palmieri DA, Wu QP, McCook EC, Serody JS. Circulating fibrocytes prepare the lung for cancer metastasis by recruiting Ly-6C+ monocytes via CCL2. J Immunol. 2013;190:4861–7.CrossRefPubMedPubMedCentral
23.
go back to reference Pedrinaci S, Algarra I, Garcia Lora A, Gaforio JJ, Perez M, Garrido F. Selective upregulation of MHC class I expression in metastatic colonies derived from tumor clones of a murine fibrosarcoma. Int J Clin Lab Res. 1999;29:166–73.CrossRefPubMed Pedrinaci S, Algarra I, Garcia Lora A, Gaforio JJ, Perez M, Garrido F. Selective upregulation of MHC class I expression in metastatic colonies derived from tumor clones of a murine fibrosarcoma. Int J Clin Lab Res. 1999;29:166–73.CrossRefPubMed
24.
go back to reference Yue S, Mu W, Zöller M. Tspan8 and CD151 promote metastasis by distinct mechanisms. Eur J Cancer. 2013;49:2934–48.CrossRefPubMed Yue S, Mu W, Zöller M. Tspan8 and CD151 promote metastasis by distinct mechanisms. Eur J Cancer. 2013;49:2934–48.CrossRefPubMed
25.
go back to reference Ji H, Greening DW, Barnes TW, Lim JW, Tauro BJ, Rai A, et al. Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics. 2013;13:1672–86.CrossRefPubMed Ji H, Greening DW, Barnes TW, Lim JW, Tauro BJ, Rai A, et al. Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics. 2013;13:1672–86.CrossRefPubMed
26.
go back to reference Thuma F, Zöller M. EpCAM-associated claudin-7 supports lymphatic spread and drug resistance in rat pancreatic cancer. Int J Cancer. 2013;133:855–66.CrossRefPubMed Thuma F, Zöller M. EpCAM-associated claudin-7 supports lymphatic spread and drug resistance in rat pancreatic cancer. Int J Cancer. 2013;133:855–66.CrossRefPubMed
27.
28.
go back to reference Galle J, Sittig D, Hanisch I, Wobus M, Wandel E, Loeffler M, et al. Individual cell-based models of tumor-environment interactions: multiple effects of CD97 on tumor invasion. Am J Pathol. 2006;169:1802–11.CrossRefPubMedPubMedCentral Galle J, Sittig D, Hanisch I, Wobus M, Wandel E, Loeffler M, et al. Individual cell-based models of tumor-environment interactions: multiple effects of CD97 on tumor invasion. Am J Pathol. 2006;169:1802–11.CrossRefPubMedPubMedCentral
29.
go back to reference Kwakkenbos MJ, Kop EN, Stacey M, Matmati M, Gordon S, Lin HH, et al. The EGF-TM7 family: a postgenomic view. Immunogenetics. 2004;55:655–66.CrossRefPubMed Kwakkenbos MJ, Kop EN, Stacey M, Matmati M, Gordon S, Lin HH, et al. The EGF-TM7 family: a postgenomic view. Immunogenetics. 2004;55:655–66.CrossRefPubMed
30.
go back to reference Wang T, Ward Y, Tian L, Lake R, Guedez L, Stetler-Stevenson WG, et al. CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood. 2005;105:2836–44.CrossRefPubMed Wang T, Ward Y, Tian L, Lake R, Guedez L, Stetler-Stevenson WG, et al. CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood. 2005;105:2836–44.CrossRefPubMed
31.
go back to reference Qian YM, Haino M, Kelly K, Song WC. Structural characterization of mouse CD97 and study of its specific interaction with murine decayaccelerating factor (DAF, CD55). Immunology. 1999;98:303–11.CrossRefPubMedPubMedCentral Qian YM, Haino M, Kelly K, Song WC. Structural characterization of mouse CD97 and study of its specific interaction with murine decayaccelerating factor (DAF, CD55). Immunology. 1999;98:303–11.CrossRefPubMedPubMedCentral
32.
go back to reference Eichler W. CD97 isoform expression in leukocytes. J Leukoc Biol. 2000;68:561–7.PubMed Eichler W. CD97 isoform expression in leukocytes. J Leukoc Biol. 2000;68:561–7.PubMed
33.
go back to reference Mikesch JH, Schier K, Roetger A, Simon R, Buerger H, Brandt B. The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy. Cell Oncol. 2006;28:223–32.PubMedPubMedCentral Mikesch JH, Schier K, Roetger A, Simon R, Buerger H, Brandt B. The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy. Cell Oncol. 2006;28:223–32.PubMedPubMedCentral
34.
go back to reference Nowicki S, Nowicki B, Pham T, Hasan R, Nagamani M. Expression of decay accelerating factor in endometrial adenocarcinoma is inversely related to the stage of tumor. Am J Reprod Immunol. 2001;46:144–8.CrossRefPubMed Nowicki S, Nowicki B, Pham T, Hasan R, Nagamani M. Expression of decay accelerating factor in endometrial adenocarcinoma is inversely related to the stage of tumor. Am J Reprod Immunol. 2001;46:144–8.CrossRefPubMed
35.
go back to reference Marhaba R, Klingbeil P, Nübel T, Nazarenko I, Büchler MW, Zöller M. CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med. 2008;8:784–804.CrossRefPubMed Marhaba R, Klingbeil P, Nübel T, Nazarenko I, Büchler MW, Zöller M. CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med. 2008;8:784–804.CrossRefPubMed
36.
go back to reference Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991;65:13–24.CrossRefPubMed Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991;65:13–24.CrossRefPubMed
37.
go back to reference Qu JL, Qu XJ, Zhao MF, Teng YE, Zhang Y, Hou KZ, et al. Gastric cancer exosomes promote tumour cell proliferation through PI3 K/Akt and MAPK/ERK activation. Dig Liver Dis. 2009;41:875–80.CrossRefPubMed Qu JL, Qu XJ, Zhao MF, Teng YE, Zhang Y, Hou KZ, et al. Gastric cancer exosomes promote tumour cell proliferation through PI3 K/Akt and MAPK/ERK activation. Dig Liver Dis. 2009;41:875–80.CrossRefPubMed
38.
go back to reference Koga K, Matsumoto K, Akiyoshi T, Kubo M, Yamanaka N, Tasaki A, et al. Purification, characterization and biological significance of tumor-derived exosomes. Anticancer Res. 2005;25:3703–7.PubMed Koga K, Matsumoto K, Akiyoshi T, Kubo M, Yamanaka N, Tasaki A, et al. Purification, characterization and biological significance of tumor-derived exosomes. Anticancer Res. 2005;25:3703–7.PubMed
39.
go back to reference Klingbeil P, Marhaba R, Jung T, Ludwig T, Zöller M. CD44 variant isoforms promote metastasis formation by a tumor cell-matrix crosstalk that supports adhesion and apoptosis resistance. Mol Cancer Res. 2009;7:168–79.CrossRefPubMed Klingbeil P, Marhaba R, Jung T, Ludwig T, Zöller M. CD44 variant isoforms promote metastasis formation by a tumor cell-matrix crosstalk that supports adhesion and apoptosis resistance. Mol Cancer Res. 2009;7:168–79.CrossRefPubMed
40.
go back to reference Kwon MJ, Park S, Choi JY, Oh E, Kim YJ, Park YH, et al. Clinical significance of CD151 overexpression in subtypes of invasive breast cancer. Br J Cancer. 2012;106:923–30.CrossRefPubMedPubMedCentral Kwon MJ, Park S, Choi JY, Oh E, Kim YJ, Park YH, et al. Clinical significance of CD151 overexpression in subtypes of invasive breast cancer. Br J Cancer. 2012;106:923–30.CrossRefPubMedPubMedCentral
41.
go back to reference Kwakkenbos MJ, Matmati M, Madsen O, Pouwels W, Wang Y, Bontrop RE, et al. An unusual mode of concerted evolution of the EGF-TM7 receptor chimera EMR2. FASEB J. 2006;20:2582–4.CrossRefPubMed Kwakkenbos MJ, Matmati M, Madsen O, Pouwels W, Wang Y, Bontrop RE, et al. An unusual mode of concerted evolution of the EGF-TM7 receptor chimera EMR2. FASEB J. 2006;20:2582–4.CrossRefPubMed
Metadata
Title
CD97 promotion of gastric carcinoma lymphatic metastasis is exosome dependent
Authors
Daren Liu
Chao Li
Bogusz Trojanowicz
Xiaowen Li
Dike Shi
Chenni Zhan
Zhefang Wang
Li Chen
Publication date
01-07-2016
Publisher
Springer Japan
Published in
Gastric Cancer / Issue 3/2016
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-015-0523-y

Other articles of this Issue 3/2016

Gastric Cancer 3/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.